Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer

NCT03627728 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Regorafenib
OTHER: placebo

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica

Collaborators

[object Object]